This nonopioid veterinary tranquilizer, which is not approved for human use, is linked to an alarming number of drug overdose deaths across the United States.

Multidisciplinary collaboration coupled with the use of multimodal strategies has enabled the tailoring of treatment plans based on the patient’s medical status and type of surgery.

The focus of new agents for treating this malignancy has been on patients with relapsed or refractory disease, which carries a poor prognosis and short life expectancy.